AVROBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 USD | -0.81% |
|
+0.83% | -10.29% |
| Mar. 21 | North American Morning Briefing : Investors -2- | DJ |
| Mar. 14 | AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presenter SpeechGeoff MacKay (Executives)Hello, everybody. I'd like to welcome you to those wh...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.22
USD
Average target price
2
USD
Spread / Average Target
+63.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.29% | 55.18M | |
| -1.43% | 103B | |
| +8.96% | 101B | |
| +4.40% | 23.07B | |
| -12.15% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.04% | 16.94B | |
| +6.79% | 14.07B | |
| +38.61% | 12.35B |
- Stock Market
- Equities
- AVRO Stock
- News AVROBIO, Inc.
- Transcript : AVROBIO, Inc. Presents at 16th Annual WORLDSymposium 2020, Feb-10-2020 through Feb-13-2020
